Imprinting disorders (IDs) are a group of congenital diseases affecting growth, development and metabolism. They are caused by changes in the allele-specific regulation ("epigenetic mutation") or in the genomic sequence ("genetic mutation") of imprinted genes. Currently molecular tests in ID patients are generally restricted to single loci classically associated with the disease, but this approach limits diagnostic yield, because of the molecular and clinical heterogeneity between IDs. From the technical point of view, these limitations are aggravated by the lack of standardization in testing methodology, in the DNA sequences tested, and in clinical inclusion criteria prompting testing.
Introduction
Imprinting disorders (IDs) are a group of congenital diseases affecting growth, development and metabolism characterised by similar molecular alterations (Table 1) .
They are caused by changes in the allele-specific regulation ("epigenetic mutation") or in the genomic sequence ("genetic mutation") of imprinted genes and regions, respectively ( Figure   1 ). In contrast to the majority of biallelically expressed genes, imprinted genes are expressed monoallelically in a parent-of-origin specific manner -i.e. either from the maternal or the paternal allele (for review: [1] ). At the molecular level, the expression of genes within imprinted regions is influenced by specific patterns of DNA methylation, changes in chromatin structure, and post-translational histone modifications, collectively designated as epigenetic regulation (for review: [2, 3] ). So far, more than 90 human genes have been confirmed to be imprinted, but there are probably more based on bioinformatics predictions Their programming is subject to an imprinting cycle during life which leads to a reprogramming at each generation (for review: [4, 5] ). Methylation of the mammalian genome is comprehensively remodelled in early development. However, imprinting marks are exempted from developmental reprogramming; instead, they are erased in the germ-line and re-established according to the sex of the contributing parent for the next generation. Many genes regulated by genomic imprinting are found in clusters, i.e. imprinted loci often comprise multiple genes under coordinated control. A prominent example is the chromosomal region 11p15.5 which harbors genes encoding several growth promoting and inhibiting factors. It spans around 1 Megabase (Mb) and maintains two separate imprinting control regions (ICRs): the telomeric imprinting control region 1 (ICR1; H19 differentially methylated region -DMR) is methylated on the paternal allele, whereas the centromeric ICR2 (KvDMR1; KCNQ1OT1 DMR) is maternally methylated. In addition to its central physiological role in human growth and development it has been postulated that the 11p15.5 region is a central element of a network of imprinted genes [6, 7] . (table 1) For the majority of the known IDs and their molecular defects, the pathophysiological mechanisms resulting in the specific phenotypes are unknown. So far only three genes have been shown to be directly associated with clinical phenotypes (Table 1) : CDKN1C in Beckwith-Wiedemann syndrome and Silver-Russell-Syndrome (BWS, SRS), UBE3A in Angelman syndrome (AS) and MKRN3 in central precocious puberty [8] . These genes are themselves imprinted; as a result, the inheritance of mutations in UBE3A and CDKN1C is autosomal dominant but its penetrance depends on the sex of the contributing parent.
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The impact of genomic mutations in imprinted genes on the clinical outcome has furthermore been shown for mental retardation: maternally inherited KCNK9 mutations have been identified to cause the Birk-Barel mental retardation syndrome [9] .
An indirect cause of IDs is the mutation of genes encoding factors involved in the establishment and maintenance of imprinting. One such factor is the ZFP57 gene mutations in which cause MLID and is inherited in an autosomal recessive manner. Interestingly, ZFP57 mutations have never been except in association with clinical presentation of transient neonatal diabetes mellitus (TNDM), An additional group of factors associated with aberrant methylation are the NLRP genes, but mutations in these genes act as maternal effect mutations, that means the maternal genotype causes aberrant methylation in the offspring [10, 11] .
So far, ten IDs have been reported (Table 1) Nearly all patients with an ID are diagnosed in (early) childhood. However, clinical diagnosis is often hampered by the breadth of the phenotypic features which are sometimes subtle, overlapping and transient; this latter point in particular can obscure diagnosis in puberty and adulthood. As a result some IDs and a proportion of patients are probably either mis-or undiagnosed.
Currently applied single-locus tests and their limitations
Up to now, molecular tests in ID patients are generally restricted to single disease-specific loci. Thus, the detection rates for epimutations or mutations at these loci are more or less well established. However, technical, biological and clinical factors influence the diagnostic yield in IDs, and thereby limit the diagnostic detection rates.
Limitation 1: lack of standardization of the applied tests
A broad range of molecular techniques with different sensitivities is applied in diagnostic testing of IDs (Table 2 ), and they often target different differentially methylated CpG dinucleotides and even different differentially methylated regions (Figure 2 ). Due to this lack of standardization, it is difficult to compare the molecular results between different studies or laboratories offering molecular diagnosis for the same disorder. However, as data for the GNAS locus reveals, the heterogeneity of molecular tests affects the detection of mosaic (epi)mutations rather than the correctness of the molecular diagnosis [12] .
Limitation 2: Heterogeneity of the aetiology in IDs
The heterogeneity of molecular aetiology in IDs has become apparent with the increased use of methods capable of parallel detection of mutations and epimutations at different loci
(multilocus methylation tests, array typing, Next Generation Sequencing/NGS; Table 3 ).
Recently, we reported on our results from a cohort of 711 patients referred with the clinical diagnosis of one of the two chromosome 11p15-associated IDs, SRS (n=571) or BWS (n=140). Molecular testing was not restricted to the 11p15 imprinted loci, but also encompassed differentially methylated regions (DMRs) on chromosomes 6, 7, 14 and 15 [13] .
In the course of this study, several patients were identified with unexpected alterations, affecting other loci than those on chromosome 11. These non-11p15 disturbances eluded routine diagnostic screening restricted to 11p15, but have significant impacts because they (a) help to define novel connections between imprinting disturbances and clinical features, and (b) increase the diagnostic yield [14] .
As already mentioned, some IDs frequently show somatic mosaicism. This is particularly recognized for epimutations in SRS and BWS. The level of mosaicism shows a broad range, and can differ remarkably between different tissues [15, 16] . Therefore, if the tissue source of the diagnostic DNA sample has a level of mosaicism below the sensitivity of the diagnostic test, the result will be negative and the patient will escape diagnosis. The limited sensitivity of current single-locus tests therefore restricts diagnostic yield. Another limitation of the single-locus tests is that many of them do not differentiate different classes of mutations and epimutations associated with IDs (e.g. UPD, epimutation) ( Figure 1 , Table 2 ).
Limitation 3: ambiguous findings in IDs
Ambiguous clinical findings in IDs further challenge the value of current single-locus tests.
The same clinical diagnosis may be associated with molecular alterations at different DMRs (e.g. ICR1 and ICR2 in 11p15 in BWS) and even at chromosomal loci (e.g. SRS: chromosomes 7 and 11; Table 1 ). This locus heterogeneity is further complicated by the possible occurrence of up to four different classes of mutations or epimutations. A prominent example is the recent discovery that CDKN1C gain-of-function mutations are associated with a clinical presentation very similar to SRS; this new aetiology complements the known causes of SRS clinical features, which include ICR1 hypomethylation, maternal UPD11 and 11p15 duplications [17, 18, 19, 20] , not to mention maternal UPD7, and chromosomal aberrations.
The broadening of molecular testing shows that there is a considerable overlap between the different IDs, and the application of single-locus test can prevent the diagnosis of basic molecular defects and thus leave a patient without diagnosis. One example is the changing phenotype in the previously identified Temple syndrome (TS14), a congenital disorder linked
to imprinted loci on 14q32. Until recently, TS14 was regarded as a differential molecular diagnosis of Prader-Willi syndrome (PWS), but the broadening of genetic testing shows that the TS14 phenotype is heterogeneous, overlaps in early childhood with that of SRS, and is not mandatorily associated with (mild) psychomotoric retardation [21] . The impressive result of the application of multilocus tests in ID diagnostics is therefore obvious as a growing number of patients with Temple syndrome (TS14) can be identified among patients referred as SRS [22] . This illustrates the need for a comprehensive diagnostic algorithm in the testing of SRS.
Furthermore, a considerable number of ID patients exhibit the above mentioned aberrant methylation at different imprinted loci (multilocus imprinting disturbances; MLID) [23] or carry at least two different molecular disturbances [24, 25] which escape single-locus testing.
These patients often show a broad clinical spectrum and the phenotype may be ambiguous or even atypical for any known ID. In summary, as Table 1 shows, a similar molecular heterogeneity is known for the majority of IDs, and this heterogeneity is not captured by many of the available tests ( Table 2 ).
Translational use of new techniques in IDs
An increasing number of new studies show that the aforementioned problems in diagnosis and investigation of IDs can be addressed by the use of new tests targeting multiple loci and/or a total exome and genome analysis.
One major prerequisite for the comprehensive diagnostic analysis of ID loci is the identification and definition of a standardized set of imprinted loci, DMRs and CpG islands.
With the extensive characterization of imprinted methylation in molecularly normal and aberrant human tissues by a combination of whole-genome bisulfite sequencing and highdensity methylation microarrays, Court and colleagues [26] Another example for the impact of multilocus testing in IDs is the growing number of reports on BWS patients with a mosaic genome-wide paternal diploidy meaning that a significant ratio of cells carry chromosomes exclusively derived from the father. It turns out that a considerable number of BWS patients diagnosed to have an UPD(11p15)pat carry this unusual aberration [13] , Considering that UPD(11p15)pat accounts for nearly 20% of BWS patients, and that carriers of a mosaic genome-wide paternal diploidy exhibit particularly unusual tumor histories which are not covered by the already existing surveillance programs for classical BWS [28] , every case of UPD(11)pat warrants testing for genome-wide uniparental diploidy [29] .
As already mentioned, somatic mosaicism is a common finding in IDs. In particular in the 11p15-associated disorders (BWS and SRS), nearly all patients with epimutations and UPD show mosaicism (for review: [13] ). As a consequence of mosaicism, the molecular alterations currently often escape diagnostic detection in case of a low level mosaicism [30] , an unequal distribution in different tissues [15] , or an insufficient sensitivity of assays [31, 32] . New diagnostic approaches therefore may analyze different tissues from the same patient as well as apply multilocus and/or deep-sequencing tests.
The suitability of genome-wide SNP arrays for mosaicism detection has recently been demonstrated by Keren et al. [29] . Their data exhibited that SNP arrays are useful tools to estimate the sizes and mosaicism rates of UPD(11p15)pat as the basis for a more precise genotype phenotype correlation. The power to detect low-level mosaicism by array analysis was additionally confirmed by Prickett et al. [33] in a cohort of SRS patients: by hybridization of patients DNA onto DNA methylation microarrays the group provided proof of principle that this technique has a higher sensitivity than classical conventional singlelocus tests. Additionally, the use of methylation arrays contributes to the idenfication of novel candidate imprinted genes, and the epigenomic profiling expands the understanding of normal methylome and its disruption [34] .
For the same purposes, deep-sequencing NGS assays have been developed, and it has been shown that this technique is able to detect even low-level mosaicism [31, 32] . As it is generally observed for genetic testing, NGS will also improve the diagnostic workup in imprinting disorders, even in so far unexpected fields like non-invasive prenatal testing [35] .
The new techniques contribute to the understanding of the pathoetiology of IDs
The aforementioned examples show that the application of multilocus and deep sequencing molecular tests are needed in ID diagnostics.
However, diagnostics and research should be regarded not as separate, but synergistic: the identification of new molecular alterations in ID patients enlighten the pathomechanisms in these heterogeneous disorders, while the data obtained from research strategies are translationally used for the improvement of diagnostic workups (Figure 3 ). This close relation between research and diagnostics will be illustrated with the following examples.
ZFP57 mutations causing autosomal-recessively inherited IDs
In seven consanguineous families affected by the ID transient neonatal diabetes the genomewide SNP array analysis delineated a single shared ~15Mb region of homozygosity on chromosome 6. Prioritization of candidate genes within this region prompted Sanger sequencing of the zinc-finger transcription factor ZFP57, which was shown to be mutated in all the consanguineous pedigrees [36] . ZFP57 was independently shown in mouse to be essential for maintenance of imprinting marks in early development [37] . Moreover, in ethnicities with a high social rate of consanguineous union, ZFP57 mutations may be the major cause of transient neonatal diabetes [38] .
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Families with NLRP mutations
Mutations of NLRP family genes NLRP7 and NLRP2 are associated with reproductive loss, where the females with these mutations gave birth to few or no liveborn children. Instead hydatidiform molar pregnancies with loss of maternal imprinting marks occurred. Caliebe et al. [39] reported exhaustive genetic and epigenetic analysis of a pedigree with two children with MLID. Exome sequencing identified a heterozygous missense variant in NLRP7 in the mother of the children. Interestingly, she had inherited this variant from her mother and both genome-wide and targeted DNA methylation analysis showed that she, like her offspring, had MLID.
Identification of CDKN1C mutations as monogenetic causes of ID phenotypes
As with other genetic fields, deep sequencing NGS has significantly contributed to the understanding of IDs. Loss-of-function CDKN1C mutations are well known to be associated with BWS, but the first gain-of-function variants have been identified in patients with IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, genitourinary abnormalities) [40] and later in SRS [20] . This finding was remarkable in at least three different ways: (a) functionally, the opposite phenotypic outcomes of BWS vs. IMAGe/SRS could be explained by the opposite functional properties of the mutations (for review: [41] ); (b) gain-of-function mutations cause growth restriction only in maternal inheritance, because CDKN1C is expressed only from the maternal allele, and therefore IMAGe syndrome can be regarded as an ID; (c) CDKN1C also illustrated the limitations of NGS. Due to its high GC content, the NGS coverage for CDKN1C was much lower than for other genomic regions, and was only identified after its sequence was reanalyzed with the Sanger method [40] , and furthermore, the bioinformatics analysis had to be adapted to a pedigree model with an influence of the parent-of-origin of putative mutations.
NGS-based quantification of aberrant methylation contributes to the understanding of regulation of imprinting centers
As it could be recently shown by Beygo et al. [32] , NGS-based approaches can also help to understand the functional interaction between different DMRs on the same imprinting center.
One example is the chromosomal region 14q32, harboring the IG-DMR and the MEG3-DMR,.Genetic aberrations affecting these DMRs are associated with TS14 or Kagami-Ogata 
Consequences of comprehensive analyses in IDs for their therapy
As already shown, the application of the new comprehensive and efficient laboratory tests in the diagnostic of IDs is resulting in an increase of patients with a molecular proven disorder.
In particular the use of multilocus tests helps to identify patients with unexpected molecular alterations (e.g. with TS14-specific alterations in a cohort of SRS patients), to enlighten the molecular basis in case of unusual phenotypes [24] and to detect MLID carriers. In the latter group, it is currently discussed whether patients with MLID and a specific ID diagnosis have phenotypes different from those with "isolated" epimutations or mutations restricted to the disease-specific locus. Here further data are needed, however due to the first reports of monogenetic causes in MLID, genetic counselling might be different.
In general, the more precise determination of the molecular basis of a clinical picture is the basis for a more personalized treatment and management. One example is the recently reported evidence for different responses of SRS patients with different molecular disturbances on growth hormone treatment [43] . These findings can be regarded as a first step towards a more individual GH substitution. Another ideal example is the identification of genome-wide uniparental diploidy patients in the group of BWS patients: these patients' tumor history and risks are different from those of UPD11pat alone, and therefore require another tumor surveillance program [28] . Tables and Figures   Table 1 :
The known congenital disorders associated with disturbances at imprinted loci, their frequencies, and the associated molecular and clinical findings. ( NR not yet reported, IUGR intrauterine growth retardation, PNGR postnatal growth retardation, PTH parathormone; hypom. hypomethylation; hyperm. hypermethylation)(*absolute numbers for the frequencies of the molecular subtypes are taken from representative studies or reviews; ** in case of AS and PWS these frequencies are well established from huge cohorts and therefore not documented by specific references) Table 2 :
Methylation-specific (MS) assays applied in diagnostics and research of imprinted loci. 
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Highlights -Imprinting disorders (IDs) are a group of congenital diseases affecting growth, development and metabolism.
-IDs are caused by changes in the allele-specific regulation ("epigenetic mutation") or in the genomic sequence ("genetic mutation") of imprinted genes.
-The application of single locus tests restrict diagnostic yield.
-A standardization in testing methodology, in the DNA sequences tested, and in clinical inclusion criteria prompting testing is urgently needed.
-The application of efficient and hight-throughput molecular techniques lead to an impressive increase of knowledge on IDs and their basic pathomechanisms.
-The diagnostic strategies will be based on standardized protocols, and provide the backbone for directed counselling, more personalized management, and new therapeutic approaches.
